<DOC>
	<DOCNO>NCT00904995</DOCNO>
	<brief_summary>Objectives : To investigate relationship administration intravenous ( IV ) oral voriconazole ( vori ) occurrence false positive ( 1,3 ) beta-d- glucan ( BG ) relative standard assessment criterion use diagnose invasive fungal infection patient hematologic malignancy .</brief_summary>
	<brief_title>Beta Glucan Assay Patients Receiving Voriconazole Prophylaxis</brief_title>
	<detailed_description>Chemotherapy low immune system function , cause fungal infection occur easily . These fungal infection find certain blood test . One blood test look part fungal cell float freely human blood . When certain drug give patient prevent fungal infection , blood test may show infection actually one present . Some drug similar study drug voriconazole . The Study Drug : Voriconazole design slow growth fungal cell , may cause fungal cell die . Screening Tests : Signing consent form mean able take part study . You `` screen test '' help doctor decide eligible take part study . The following test procedure perform : - Your medical history record . - You complete physical exam . - Blood ( 1 teaspoon ) drawn routine test . - If doctor think need , chest x-ray compute tomography ( CT ) scan chest check pneumonia . The study doctor discus screen test result . If screening test show eligible take part study , enrol . Other treatment option discuss . Study Groups : If find eligible take part study , assign 1 2 study group . Group 1 consist first 10 patient enrol study . Group 2 consist next 10 patient enrol study . If Group 1 , take pill study drug 2 time every day study . If Group 2 , receive study drug needle vein 1 time begin study take pill study drug 2 time every day rest time study . Blood Draws Fungal Infection Tests : If Group 1 , blood ( 1 teaspoon time ) drawn fungal infection test follow time : - Before first dose study drug . - 1 , 2 , 4 , 8 hour first dose study drug . - Before third dose study drug . - 1 , 2 , 4 , 8 hour third dose study drug . If Group 2 , blood ( 1 teaspoon time ) drawn fungal infection test follow time : - Before first dose study drug . - 1 , 2 , 4 , 8 hour first dose study drug . - 1 , 2 , 4 hour second dose study drug . Length Study : You may continue take study drug 35 day receive chemotherapy first time 42 day chemotherapy . Your doctor may decide take study drug even longer period time need another drug prevent fungal infection . You take study intolerable side effect occur get fungal infection . Additional Information : There several drug take combination voriconazole . You talk study doctor drug may take drug may plan start take study . You also avoid eating/drinking grapefruit/grapefruit product study , may interfere effect study drug . This investigational study . Voriconazole FDA approve commercially available treatment fungal infection . Up 20 patient find eligible screen take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>1 . Diagnosis hematologic malignancy indication receive antifungal prophylaxis . 2 . Age &gt; /= 18 year . 3 . Patients must sign informed consent . 1 . Patients history anaphylaxis attribute azole compound : voriconazole , itraconazole , fluconazole , posaconazole 2 . Patients clinical evidence indicate proven probable invasive fungal infection prior enrollment ( European Organisation Research Treatment Cancer ( EORTC ) criterion ) . 3 . Patients total bilirubin level &gt; 3 time upper normal limit ( i.e . &gt; 3.0 mg/dl ) ; aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) &gt; 5 time upper limit normal . 4 . Patients receive medication contraindicate use voriconazole . Voriconazole contraindicate coadministration follow drug : sirolimus , terfenadine , astemizole , cisapride , pimozide , quinidine , ergot alkaloid , rifabutin , rifampin , highdose ritonavir ( 400 mg Q12h ) , carbamazepine , longacting barbiturate , efavirenz ( standard dose vfend efavirenz ) , St. John 's Wort . 5 . Patients currently receive voriconazole antifungal prophylaxis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Cancer blood</keyword>
	<keyword>Cancer bone marrow</keyword>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Invasive fungal infection</keyword>
	<keyword>Voriconazole</keyword>
	<keyword>Vfend</keyword>
	<keyword>antifungal prophylaxis</keyword>
</DOC>